Evaluation of liposomal ciprofloxacin formulations in a murine model of anthrax.
The in vivo efficacy of liposomal encapsulated ciprofloxacin in two formulations, lipoquin and apulmiq, were evaluated against the causative agent of anthrax, Bacillus anthracis. Liposomal encapsulated ciprofloxacin is attractive as a therapy since it allows for once daily dosing and achieves higher...
Main Authors: | Chad W Stratilo, Scott Jager, Melissa Crichton, James D Blanchard |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2020-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0228162 |
Similar Items
-
Development of Liposomal Ciprofloxacin to Treat Lung Infections
by: David Cipolla, et al.
Published: (2016-03-01) -
The potential of liposome–encapsulated ciprofloxacin as a tularemia therapy
by: Karleigh Ann Hamblin, et al.
Published: (2014-06-01) -
A New Murine Model for Gastrointestinal Anthrax Infection.
by: Tao Xie, et al.
Published: (2013-01-01) -
Decontamination Efficacy and Skin Toxicity of Two Decontaminants against Bacillus anthracis.
by: Chad W Stratilo, et al.
Published: (2015-01-01) -
Development of ciprofloxacin radiopharmaceutical formulation in single vial
by: Nurlaila Z, et al.
Published: (2010-04-01)